- Home
- ACH vs SAVA Comparison
ACH vs SAVA Comparison
Compare ACH & SAVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ACH | SAVA |
|---|---|---|
| Founded | 1882 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 179.4M | 156.5M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ACH | SAVA |
|---|---|---|
| Price | $2.36 | $2.14 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | ★ 2.2M | 1.0M |
| Earning Date | 02-27-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $10,768,859,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 132.03 | N/A |
| 52 Week Low | $1.84 | $1.15 |
| 52 Week High | $15.54 | $4.98 |
Technical Indicators
Market Signals| Indicator | ACH | SAVA |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 37.67 |
| Support Level | N/A | $1.96 |
| Resistance Level | N/A | $2.28 |
| Average True Range (ATR) | 0.00 | 0.15 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 0.00 | 18.81 |
Price Performance
Historical ComparisonAbout SAVA Cassava Sciences Inc.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.